PharmaEssentia: Returned to profitability with record revenue, strong US sales, and major R&D and capital investments
Less than 1 min read
Net income rebounded to $2.97 billion NTD in 2024 on doubled revenue and strong US sales, with robust cash reserves and ongoing R&D investment. Arbitration with AOP remains unresolved, and major capital projects are underway.
Original document: PharmaEssentia Corp. [6446] Interim report — Mar. 26 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr